Adrenal Hormone + Female Hormone Combo

Description

What is the Oestrogen Metabolites (Urinary) Test?

The Oestrogen Metabolites (Urinary) Test from BiomarkersLabs.com measures the downstream metabolic products of oestrogen detoxification in urine — providing the detailed picture of oestrogen metabolism that serum oestradiol levels alone cannot reveal. After oestrogens are biologically active at target tissues, they undergo hepatic phase I metabolism (primarily via cytochrome P450 enzymes, particularly CYP1A2, CYP1B1, and CYP3A4) into three principal hydroxylated metabolites: 2-hydroxyoestrone (2-OH E1), 4-hydroxyoestrone (4-OH E1), and 16-alpha-hydroxyoestrone (16-OH E1). These metabolites have profoundly different biological potencies and safety profiles that have important clinical relevance — particularly in the context of breast and other hormone-sensitive cancer risk.

The 2-OH pathway is considered the protective oestrogen detoxification route, producing relatively weak and rapidly cleared metabolites. The 4-OH pathway produces genotoxic catecholestrogens capable of forming DNA adducts and is associated with breast cancer risk. The 16-OH pathway produces potent oestrogenic metabolites with prolonged receptor activity, associated with stimulation of oestrogen-sensitive tissues and linked to breast cancer risk in epidemiological studies. The 2-OH:16-OH ratio is the most clinically used risk indicator — a higher ratio (more 2-OH relative to 16-OH) indicates a more protective oestrogen metabolism pattern. Phase II methylation of 2-OH oestrone to 2-methoxy-oestrone is a further protective step requiring adequate COMT enzyme activity and methyl donors. This test measures all three pathways and their methylation products, providing actionable data for oestrogen metabolism optimisation. Results are delivered within 5–7 business days. Available in USA and Canada. Licensed practitioners only.

What does the Oestrogen Metabolites (Urinary) Test measure?

2-Hydroxyoestrone (2-OH E1) — the primary protective oestrogen metabolite; relatively inert and rapidly cleared. Higher values indicate favourable oestrogen metabolism.

4-Hydroxyoestrone (4-OH E1) — the genotoxic catecholestrogen pathway metabolite; DNA adduct formation potential; elevated values indicate unfavourable metabolic routing.

16-Alpha-Hydroxyoestrone (16-OH E1) — potent proliferative oestrogen metabolite; elevated values associated with oestrogen-sensitive tissue stimulation and increased breast cancer risk in some studies.

2-OH:16-OH ratio — the primary clinical risk indicator; a ratio above 2.0 is associated with more protective oestrogen metabolism.

2-Methoxyoestrone (2-MeO E1) — the methylated product of 2-OH oestrone via COMT; reduced 2-methoxyoestrone indicates COMT enzyme deficiency, methyl donor deficiency, or methylation impairment.

Methylation index (2-MeO E1:2-OH E1 ratio) — reflects COMT methylation efficiency; guides B-vitamin and methyl donor supplementation decisions.

Clinical indications

Breast cancer risk assessment — oestrogen metabolism profiling — urinary oestrogen metabolite profiling is the primary non-genetic risk assessment tool for evaluating oestrogen detoxification pathway efficiency in women with personal or family history of breast cancer, BRCA mutation carriers, and women on long-term HRT.

HRT safety monitoring — oestrogen metabolism assessment — women on HRT, particularly long-term users, benefit from oestrogen metabolite profiling to confirm that oestrogen metabolism is proceeding through protective (2-OH) rather than genotoxic (4-OH) pathways.

COMT and methylation pathway assessment — reduced 2-methoxyoestrone and a low methylation index identifies COMT enzyme deficiency or methyl donor insufficiency, guiding interventions with methylfolate, B12, and other methyl donors.

Oestrogen dominance investigation with metabolic context — in women with clinical oestrogen dominance symptoms (heavy periods, fibrocystic breasts, endometriosis, weight gain) where serum oestradiol is normal, urinary metabolites may reveal an elevated 16-OH pathway driving oestrogenic tissue stimulation.

Functional medicine oestrogen detoxification protocol monitoring — practitioners using indole-3-carbinol, DIM, flaxseed, cruciferous vegetable protocols, or liver detoxification support to shift oestrogen metabolism towards the 2-OH pathway can use this test to monitor the efficacy of their interventions.

Endometriosis and uterine fibroid hormonal context — oestrogen metabolite patterns contribute to understanding the oestrogenic tissue stimulation driving endometriosis and fibroid growth, complementing standard serum hormone assessment.

Sample type and collection

Urine (first morning void). No fasting required. The patient collects the first-morning void urine sample into the collection vessel provided in the test kit. A single first-morning void collection is sufficient for all metabolite measurements. The sample is refrigerated after collection and mailed to the laboratory in the insulated shipping container provided with the kit. Home collection is fully suitable.

Turnaround time

5–7 business days from specimen receipt.

Availability

USA · Canada

Compliance

CLIA Certified · HIPAA Compliant · PIPEDA Compliant

How to order

Register free at BiomarkersLabs.com. Licensed practitioners only. Pay per test — no subscription required. Results are delivered directly and securely to your practitioner portal and are never released directly to patients.